Vijaya Diagnostic Centre Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Smallcap 250 and in line with its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vijaya Diagnostic Centre's board met on February 13, 2026, and approved the unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025. The board noted the resignation of Mr. S. Ramachandra Reddy as CFO due to organizational restructuring, though he will continue as General Manager – Finance & Accounts. Three new KMPs were appointed with effect from the same date: Mr. Ankit Shah as the new CFO (ex-Group CFO of Incor Hospitals/OMNI Hospitals), Mr. Sai Prasad as CTO (ex-Optum Global Solutions), and Mr. Venkata Siva Rama Raju Vegesna as COO (ex-KIMS Hospitals, previously with Vijaya Diagnostic). Two new Non-Executive Independent Directors were appointed for five-year terms: Mr. Ravi Shankararamiah (Senior Advocate) and Dr. Sasikala Paruchuri Kola (Consultant Gynaecologist). The board also granted 1,15,000 ESOPs at ₹809 per option under the VDCL ESOP Plan 2018 and revised the Related Party Transaction Policy in line with the latest SEBI circulars.
The simultaneous exit and entry at the CFO level is a key management transition, though continuity is maintained since the outgoing CFO stays on as GM – Finance & Accounts. The strengthening of the senior leadership team (new CFO, CTO, COO) and addition of two experienced independent directors should be viewed positively for governance and execution. ESOP grants and the RPT policy revision are routine governance matters and are unlikely to move the stock meaningfully.